HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steffes, M. W. Articles by Thomas, W. Search for Related Content PubMed PubMed Citation Articles by Steffes, M. W. Articles by Thomas, W. Social Bookmarking                What's this?

ß-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial

¹ Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota
² Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota
³ Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, Minnesota

In patients with type 1 diabetes, measurement of connecting peptide (C-peptide), cosecreted with insulin from the islets of Langerhans, permits estimation of remaining ß-cell secretion of insulin. In this retrospective analysis to distinguish the incremental benefits of residual ß-cell activity in type 1 diabetes, stimulated (90 min following ingestion of a mixed meal) C-peptide levels at entry in the Diabetes Control and Complications Trial (DCCT) were related to measures of diabetic retinopathy and nephropathy and to incidents of severe hypoglycemia. Based on the analytical sensitivity of the assay (0.03 nmol/l) and study entry criteria, the DCCT subjects were divided into four groups of stimulated C-peptide responses: 0.03, 0.04–0.20, 0.21–0.50 nmol/l at entry, and 0.21–0.50 nmol/l at entry and at least 1 year later (sustained C-peptide secretion). Uniformly in the intensive and partially in the conventional DCCT treatment groups, any C-peptide secretion, but especially at higher and sustained levels of stimulated C-peptide, was associated with reduced incidences of retinopathy (both a single three-step change and a repeated three-step change on the Early Treatment of Diabetic Retinopathy Study [ETDRS] scale at the next 6 month visit) and nephropathy (both albuminuria >40 mg/24 h once and repeated at the next annual visit). There were also differences in severe hypoglycemia across C-peptide levels in both treatment groups. In the intensively treated cohort there were essentially identical prevalences of severe hypoglycemia (65% of participants) in the first three groups; however, those subjects with mixed-meal stimulated C-peptide level >0.20 nmol/l for at least baseline and the first annual visit in the DCCT experienced a reduced prevalence of 30%. Therefore, even modest levels of ß-cell activity at entry in the DCCT were associated with reduced incidences of retinopathy and nephropathy. Also, continuing C-peptide (insulin) secretion is important in avoiding hypoglycemia (the major complication of intensive diabetic therapy).

Abbreviations: AER, albumin excretion rate • DCCT, Diabetes Control and Complications Trial • ETDRS, Early Treatment of Diabetic Retinopathy Study • HPLC, high-performance liquid chromatography

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. J. Brown, N. Sinaii, and K. I. Rother Too Much Glucagon, Too Little Insulin: Time course of pancreatic islet dysfunction in new-onset type 1 diabetes Diabetes Care, July 1, 2008; 31(7): 1403 - 1404. [Abstract] [Full Text] [PDF]

				A. Petrone, M. Spoletini, S. Zampetti, M. Capizzi, S. Zavarella, J. Osborn, P. Pozzilli, R. Buzzetti, and for the Immunotherapy Diabetes (IMDIAB) Group The PTPN22 1858T Gene Variant in Type 1 Diabetes Is Associated With Reduced Residual {beta}-Cell Function and Worse Metabolic Control Diabetes Care, June 1, 2008; 31(6): 1214 - 1218. [Abstract] [Full Text] [PDF]

				R. R. Little, C. L. Rohlfing, A. L. Tennill, R. W. Madsen, K. S. Polonsky, G. L. Myers, C. J. Greenbaum, J. P. Palmer, E. Rogatsky, and D. T. Stein Standardization of C-Peptide Measurements Clin. Chem., June 1, 2008; 54(6): 1023 - 1026. [Abstract] [Full Text] [PDF]

				R. Mussmann, M. Geese, F. Harder, S. Kegel, U. Andag, A. Lomow, U. Burk, D. Onichtchouk, C. Dohrmann, and M. Austen Inhibition of GSK3 Promotes Replication and Survival of Pancreatic Beta Cells J. Biol. Chem., April 20, 2007; 282(16): 12030 - 12037. [Abstract] [Full Text] [PDF]

				J. C. Voltarelli, C. E. B. Couri, A. B. P. L. Stracieri, M. C. Oliveira, D. A. Moraes, F. Pieroni, M. Coutinho, K. C. R. Malmegrim, M. C. Foss-Freitas, B. P. Simoes, et al. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus JAMA, April 11, 2007; 297(14): 1568 - 1576. [Abstract] [Full Text] [PDF]

				H.-M. Wiedmeyer, K. S. Polonsky, G. L. Myers, R. R. Little, C. J. Greenbaum, D. E. Goldstein, and J. P. Palmer International Comparison of C-Peptide Measurements Clin. Chem., April 1, 2007; 53(4): 784 - 787. [Abstract] [Full Text] [PDF]

				J. M. Sosenko, J. P. Palmer, C. J. Greenbaum, J. Mahon, C. Cowie, J. P. Krischer, H. P. Chase, N. H. White, B. Buckingham, K. C. Herold, et al. Increasing the Accuracy of Oral Glucose Tolerance Testing and Extending Its Application to Individuals With Normal Glucose Tolerance for the Prediction of Type 1 Diabetes: The Diabetes Prevention Trial-Type 1 Diabetes Care, January 1, 2007; 30(1): 38 - 42. [Abstract] [Full Text] [PDF]

				I. Y. Jarvela, J. Juutinen, P. Koskela, A.-L. Hartikainen, P. Kulmala, M. Knip, and J. S. Tapanainen Gestational Diabetes Identifies Women at Risk for Permanent Type 1 and Type 2 Diabetes in Fertile Age: Predictive role of autoantibodies. Diabetes Care, March 1, 2006; 29(3): 607 - 612. [Abstract] [Full Text] [PDF]

				J. M. Sosenko, J. P. Palmer, C. J. Greenbaum, J. Mahon, C. Cowie, J. P. Krischer, H. P. Chase, N. H. White, B. Buckingham, K. C. Herold, et al. Patterns of metabolic progression to type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care, March 1, 2006; 29(3): 643 - 649. [Abstract] [Full Text] [PDF]

				N. A. Sherry, E. B. Tsai, and K. C. Herold Natural History of {beta}-Cell Function in Type 1 Diabetes Diabetes, December 1, 2005; 54(suppl_2): S32 - S39. [Abstract] [Full Text] [PDF]

				P. Fiorina, C. Gremizzi, P. Maffi, R. Caldara, D. Tavano, L. Monti, C. Socci, F. Folli, F. Fazio, E. Astorri, et al. Islet Transplantation Is Associated With an Improvement of Cardiovascular Function in Type 1 Diabetic Kidney Transplant Patients Diabetes Care, June 1, 2005; 28(6): 1358 - 1365. [Abstract] [Full Text] [PDF]

				G. Bruno, F. Cerutti, F. Merletti, P. Cavallo-Perin, E. Gandolfo, M. Rivetti, C. Runzo, S. Pinach, G. Pagano, and The Piedmont Study Group for Diabetes Epidemiology Residual {beta}-Cell Function and Male/Female Ratio Are Higher in Incident Young Adults Than in Children: The registry of type 1 diabetes of the province of Turin, Italy, 1984-2000 Diabetes Care, February 1, 2005; 28(2): 312 - 317. [Abstract] [Full Text] [PDF]

				A. Maestroni, D. Ruggieri, G. Dell'Antonio, L. Luzi, and G. Zerbini C-peptide increases the expression of vasopressin-activated calcium-mobilizing receptor gene through a G protein-dependent pathway Eur. J. Endocrinol., January 1, 2005; 152(1): 135 - 141. [Abstract] [Full Text] [PDF]

				C. A. Hedman, J. Frystyk, T. Lindstrom, J.-W. Chen, A. Flyvbjerg, H. Orskov, and H. J Arnqvist Residual {beta}-Cell Function More than Glycemic Control Determines Abnormalities of the Insulin-Like Growth Factor System in Type 1 Diabetes J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6305 - 6309. [Abstract] [Full Text] [PDF]

				E. Ortqvist, E. Bjork, M. Wallensteen, J. Ludvigsson, J. Aman, C. Johansson, G. Forsander, F. Lindgren, L. Berglund, M. Bengtsson, et al. Temporary Preservation of {beta}-Cell Function by Diazoxide Treatment in Childhood Type 1 Diabetes Diabetes Care, September 1, 2004; 27(9): 2191 - 2197. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Diabetes Complications Diabetes Care, June 1, 2004; 27(6): 1506 - 1514. [Full Text] [PDF]

				C. Steele, W. A. Hagopian, S. Gitelman, U. Masharani, M. Cavaghan, K. I. Rother, D. Donaldson, D. M. Harlan, J. Bluestone, and K. C. Herold Insulin Secretion in Type 1 Diabetes Diabetes, February 1, 2004; 53(2): 426 - 433. [Abstract] [Full Text]

				J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001 Diabetes, January 1, 2004; 53(1): 250 - 264. [Abstract] [Full Text] [PDF]